Key clinical point: Benefit of first-line docetaxel in metastatic hormone-sensitive prostate cancer appears to hinge on molecular subtype.

Major finding: Adding docetaxel to androgen deprivation therapy significantly prolonged overall survival among men with the luminal B subtype (52.1 months vs. 29.8 months; P = .007) but not among men with the basal subtype (49.2 months vs. 47.1 months; P = .60).

Study details: A correlative analysis of 160 men with newly diagnosed metastatic hormone-sensitive prostate cancer enrolled in the phase 3 CHAARTED trial.

Disclosures: This research was funded by Decipher Biosciences and the National Institutes of Health. The CHAARTED trial was funded by the ECOG-ACRIN Cancer Research Group in collaboration with the National Cancer Institute. The presenter and discussant disclosed relationships with a range of pharmaceutical companies.